These results revealed that patients with high FARSB expression may benefit from immunotherapy for HCC, and that rational application of CTLA-4 and PD-1 or its ligands CD80 and PD-L1 inhibitors will facilitate to restore anti-tumor immune responses, which in turn will provide long-term benefits to patients. Here, CD80 is linked to hepatocellular carcinoma.